This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Dr Reddy’s Laboratories (RDY), Amgen (AMGN)

Tipranks - Tipranks - Fri Jun 19, 6:22AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dr Reddy’s Laboratories (RDY), Amgen (AMGN) and Viking Therapeutics (VKTX) with bullish sentiments.

Claim 55% Off TipRanks

Dr Reddy’s Laboratories (RDY)

According to TipRanks.com, Manpuria is ranked #5835 out of 12315 analysts.

Dr Reddy’s Laboratories has an analyst consensus of Hold, with a price target consensus of $16.16.

See Insiders’ Hot Stocks on TipRanks >>

Amgen (AMGN)

In a report released today, Luca Issi from RBC Capital reiterated a Buy rating on Amgen, with a price target of $370.00. The company’s shares closed last Wednesday at $341.66, close to its 52-week high of $346.85.

According to TipRanks.com, Issi is a 1-star analyst with an average return of -1.9% and a 38.2% success rate. Issi covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, and Lexeo Therapeutics, Inc. ;'>

Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $357.38, which is a 3.0% upside from current levels. In a report issued on June 5, Goldman Sachs also maintained a Buy rating on the stock with a $389.00 price target.

Viking Therapeutics (VKTX)

Morgan Stanley analyst Michael Ulz reiterated a Buy rating on Viking Therapeutics today and set a price target of $95.00. The company’s shares closed last Wednesday at $30.29, close to its 52-week low of $24.41.

According to TipRanks.com, Ulz is a 2-star analyst with an average return of 0.7% and a 43.7% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Kyverna Therapeutics, Inc., and Arrowhead Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viking Therapeutics with a $93.70 average price target, a 212.3% upside from current levels. In a report issued on June 9, William Blair also reiterated a Buy rating on the stock.

Read More on RDY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).